autologous genetically modified mage a10c796 t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02592577)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous genetically modified mage a10c796 t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02989064 | Phase 1 | Oct 1, 2016 | Adaptimmune, University of Texas at Houston |
| NCT02592577 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Adaptimmune, University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptimmune | For profit | 2 | 2 | 2 | 2015 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1